Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences is expected to have a successful year in 2026, with the potential of achieving peak commercial revenue in the near future. Its proprietary ABC platform, highlighted by the potential of its investigational drugs tarcocimab tedromer, KSI-501, and KSI-101, holds great promise for retinal medicine by addressing the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. This, combined with its consistently positive clinical trial results, has led to a positive outlook on the company's stock and a strong belief in its potential for continued growth.

Bears say

Kodiak Sciences is seeing potential success with their Phase 3 GLOW program and anticipates FDA submission for tarcocimab based on its favorable safety and tolerability profile. With the upcoming Phase 3 DAYBREAK trial expected to confirm both the immediate and durable benefits of tarcocimab in wet AMD, Kodiak's unique ABC platform may establish differentiation within the retinal therapeutic landscape. However, concerns remain about the current unmet need of injection burden for traditional anti-VEGF treatments and will be closely monitored as Phase 3 GLOW2 data in diabetic retinopathy is expected in 1Q26.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.